DOCSLIB.ORG

Synthetic Modifications of Estrogens and Androgens

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Synthetic Modifications of Estrogens and Androgens Synthetic Modifications of Estrogens and Androgens Somdatta Deb University of Helsinki Faculty of Science Department of Chemistry Laboratory of Organic Chemistry Finland ACADEMIC DISSERTATION To be presented with the permission of the Faculty of Scienec of the University of Helsinki for public criticism in Auditorium A110, Department of Chemistry on June 23rd, 2011, at 12 o’clock. Helsinki 2011 Supervisor Professor Kristiina Wähälä Laboratory of Organic Chemistry Department of Chemistry University of Helsinki Finland Reviewers Professor Erkki Kolehmainen Department of Chemistry University of Jyväskyla Finland Docent Salme Koskimies Adjunct. Professor University of Helsinki Opponent Professor Maria Christina das Neves Oliveira Unidade de Ciências Químicas e Radiofarmacêuticas Portugal ISBN 978-952-92-9174-8 (paperback) ISBN 978-952-10-7051-8 (PDF) Helsinki 2011 Unigrafia Acknowledgements This thesis work was carried out at the Laboratory of Organic Chemistry, Department of Chemistry, University of Helsinki. I would like to express my deep gratitude to my supervisor Prof. Kristiina Wähälä for introducing me to the fascinating field of steroid chemistry and for providing the facilities to do this work. I warmly thank emeritus professor Tapio Hase for his helpful, invaluable scientific advice during my work. Prof. Matti J. Tikkananen and his group are gratefully acknowledged for pleasant collaboration. My warmest thanks are due to all personnel in the Laboratory of Organic Chemistry, specially the members (former and present) of Phyto-Syn group for their support. They have been always there when needed. In particular I would like to thank Gudrun Silvennoinen for technical assistance and friendship. I am thankful to Dr. Ullastiina Hakala for introducing me to the field of ionic liquid. Thank you Lea for being such a good friend. I am also grateful to Dr. Sami Heikkinen for his expertise in NMR spectroscopy and assistance. I extend my thanks to Dr. Jorma Matikainen for advising me in mass spectrometry. I also thank Maiju Soikkeli for technical assistance. Special thanks are owed to Dr. Jorma Koskimies and Dr. Leena Kaisalo for their generous help in any matter. Professor Erkki Kolehmainen and Docent Salme Koskimies are warmly acknowledged for reviewing the manuscript of this thesis. They gave their comments remarkably fast. I would like to take this opportunity to thank my friends and former teachers in India who induces passion for research in me. My sincerest appreciation goes to my parents for encouragement and versatile support. I am deeply indebted to my late mother for sowing logical thinking seed in me. I thank my husband Suvendu Mitra for his patience, love and encouragement during these years. I am grateful to him for listening and understanding during the most difficult time. Helsinki, May 2011 Somdatta Deb CONTENTS Abstract............................................................................................................................................... 4 Abbreviations..................................................................................................................................... 6 1. INTRODUCTION ........................................................................................................................ 8 2. LITERATURE REVIEW.........................................................................................................14 2.1 C-7 substituted estrogen.........................................................................................................................14 2.1.1 Synthesis of C-7 alkyl substituted estrogen by converting other steroids to estrogen ...................................................................................................................................................................... 15 2.1.2 Direct addition of substituent to C-7 of estrane skeleton ............................................... 19 2.1.3 Synthesis of 7-hydroxyestrone and estradiol...................................................................... 26 2.2 Studies on 8-isoestrogens.......................................................................................................................28 2.3 Immunoassay ..............................................................................................................................................30 2.4 Fatty acid esters of steroids ..................................................................................................................33 3. AIMS OF STUDY ......................................................................................................................38 4. RESULTS AND DISCUSSION ...............................................................................................39 4.1 Synthesis of estriol ....................................................................................................................................39 4.2 Protection of hydroxyl groups of estradiol and estriol...............................................................42 4.3 Oxidation at C-6 of estradiol and estriol.........................................................................................44 4.4 Alkylation at C-7........................................................................................................................................47 4.5 Hydroxylation and etherification at C-7..........................................................................................54 4.6 Synthesis of 8-isoestradiol derivative................................................................................................57 4.7 Selective debenzylation ...........................................................................................................................59 4.8 Synthesis of steroid fatty acid esters..................................................................................................65 5. CONCLUSION ...........................................................................................................................69 6. EXPERIMENTAL .....................................................................................................................70 6.1 General methods........................................................................................................................................70 6.2 Synthesis of estriol ....................................................................................................................................70 6.2.1 Synthesis of 3-acetoxyestra-1,3,5(10)16-tetraene-17-one (111) ................................. 70 6.2.2 Synthesis of 3,17β-diacetoxyestra-1,3,5(10)16-tetraene (114).................................... 71 6.2.3 Synthesis of 16α,17α-epoxy-estra-1,3,5(10)triene-3,17β-diol diacetate (116)...... 71 6.2.4 Reduction of 116 with LAH (normal addition)................................................................. 72 6.2.5 Reduction of 78 with LAH (inverse addition) ................................................................... 72 6.2.6 Synthesis of estriol (3) ............................................................................................................... 72 6.3 Protection of estriol..................................................................................................................................74 6.3.1 Attempted protection of estriol as triisopropylsilyl ether (117) with imidazole and TIPSCl........................................................................................................................................................ 74 6.3.2 Protection of estriol as tert-butyl ether (118) with isobutylene and Amberlyst-1574 6.3.3 Synthesis of estra-1,3,5(10)-triene-3,16α,17β-triol-3,16,17-tris(methoxymethyl) ether (122)................................................................................................................................................. 76 6.4 C-6 oxidation of estradiol......................................................................................................................76 6.4.1 Synthesis of estra-1,3,5(10)-triene-3,17β-diol diacetate (123) .................................... 76 6.4.2 Synthesis of 6-oxo-estra-1,3,5(10)-triene-3,17β-diol diacetate (124) (oxidation with CrO3/ 3,5-dimethyl pyrazole) ................................................................................................... 77 6.4.3 Synthesis of estra-1,3,5(10)-triene-3,17β-diol dibenzoate (125)................................. 77 6.4.4 Synthesis of 6-oxo-estra-1,3,5(10)-triene-3,17β-diol dibenzoate (126) (oxidation with K2S2O8/CuSO4.5H2O) ................................................................................................................. 78 6.4.5 Synthesis of estra-1,3,5(10)-triene-3,17β-diol-3,17-di-tert-butyl ether (127) ........ 78 1 6.4.6 Synthesis of 6-hydroxy-estra-1,3,5(10)-triene-3,17β-diol-3,17di-tert-butyl ether (130)............................................................................................................................................................ 79 6.4.7 Oxidation of 130 to 6-oxo-estra-1,3,5(10)-triene-3,17β-diol-3,17di-tert-butyl ether (129)............................................................................................................................................................ 80 6.5 Oxidation of estriol...................................................................................................................................80 6.5.1 Oxidation of 131
Load more

Recommended publications
  • Compositions Comprising Drospirenone Molecularly
    (19) & (11) EP 1 748 756 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/107 (2006.01) 29.04.2009 Bulletin 2009/18 A61K 9/48 (2006.01) A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 9/14 (2006.01) (2006.01) (2006.01) (21) Application number: 05708751.2 A61K 9/70 A61K 31/565 (22) Date of filing: 10.03.2005 (86) International application number: PCT/IB2005/000665 (87) International publication number: WO 2005/087194 (22.09.2005 Gazette 2005/38) (54) COMPOSITIONS COMPRISING DROSPIRENONE MOLECULARLY DISPERSED ZUSAMMENSETZUNGEN AUS DROSPIRENON IN MOLEKULARER DISPERSION DES COMPOSITIONS CONTENANT DROSPIRENONE A DISPERSION MOLECULAIRE (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • FUNKE, Adrian HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR D-14055 Berlin (DE) Designated Extension States: • WAGNER, Torsten AL BA HR MK YU 13127 Berlin (DE) (30) Priority: 10.03.2004 EP 04075713 (74) Representative: Wagner, Kim 10.03.2004 US 551355 P Plougmann & Vingtoft a/s Sundkrogsgade 9 (43) Date of publication of application: P.O. Box 831 07.02.2007 Bulletin 2007/06 2100 Copenhagen Ø (DK) (60) Divisional application: (56) References cited: 08011577.7 / 1 980 242 EP-A- 1 260 225 EP-A- 1 380 301 WO-A-01/52857 WO-A-20/04022065 (73) Proprietor: Bayer Schering Pharma WO-A-20/04041289 US-A- 5 569 652 Aktiengesellschaft US-A- 5 656 622 US-A- 5 789 442 13353 Berlin (DE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,828,435 B2 Hewitt Et Al
    USOO88284.35B2 (12) United States Patent (10) Patent No.: US 8,828,435 B2 Hewitt et al. (45) Date of Patent: Sep. 9, 2014 (54) BUCCAL DELIVERY SYSTEM 2002/0114833 A1 8/2002 Abu-IZZa et al. 2004/0019026 A1 1/2004 Schwartz ...................... 514,177 2004/0028732 A1 2/2004 Falkenhausen et al. (75) Inventors: Ernest Alan Hewitt, Windsor Downs 2004/0037878 A1 2/2004 Szamosi et al. (AU); Richard James Stenlake, Double 2006, O141027 A1 6, 2006 Cioli Day (AU) FOREIGN PATENT DOCUMENTS (73) Assignee: Lingual Consegna Pty Ltd (AU) EP 215635 3, 1987 (*) Notice: Subject to any disclaimer, the term of this GB 1248.189 9, 1971 patent is extended or adjusted under 35 W. wo: iii. U.S.C. 154(b) by 85 days. WO WO9904758 2, 1999 WO WOO189485 11, 2001 (21) Appl. No.: 13/021,578 WO 2004075877 A1 9, 2004 (22) Filed: Feb. 4, 2011 OTHER PUBLICATIONS (65) Prior Publication Data Velaz I., et al., “Effect of PEG 4000 on the Dissolution Rate of Naproxen”, European Journal of Drug Metabolism & US 2011 FO123619 A1 May 26, 2011 Pharmacokinetics, vol. 23, No. 2, pp. 103-108 (Apr.-Jun. 1998). Runkel, R., et al., "Naproxen Oral Absorption Characteristics'. Related U.S. Application Data Chem. Pharm. Bull. vol. 70, No. 7, pp. 1457-1466 (197p). Ranucci E. et al., “Pharmacokinetic Results on Naproxen Prodrugs (63) Continuation of application No. 1 1/910.902, filed as Based on Poly(ethyleneglycol)s', J Biomater Sci Polymer Edn, vol. application No. PCT/AU2006/000472 on Apr. 7, 2006, 6, No.
    [Show full text]
  • Silicone Polymers in Controlled Drug Delivery Systems: a Review Iranian Polymer Journal 18 (4), 2009, 279-295
    Available online at: http://journal.ippi.ac.ir Silicone Polymers in Controlled Drug Delivery Systems: A Review Iranian Polymer Journal 18 (4), 2009, 279-295 Arezou Mashak and Azam Rahimi* Iran Polymer and Petrochemical Institute, P.O. Box: 14965-115, Tehran, Iran Received 15 October 2008; accepted 4 April 2009 ABSTRACT n this paper some of the latest studies and research works conducted on silicone- based drug delivery systems (DDS) are reviewed and some of more specific and Iimportant novel drug delivery devices are discussed in detail. An overview on rapidly growing developments on silicone-based drug delivery systems is provided by presenting the necessary fundamental knowledge on silicone polymers and a literature survey including an introductory account on some of the drugs that are diffused through silicone polymers. The results based on vast investigations over a period of a decade indicate that intravaginal and transdermal routes of administration of the drugs using silicone-based DDS are more developed. It is also found that silicone polymers are suitable candidates for the release of hormonal steroids for controlling the estrous cycle. Finally, some commercially available silicone-based DDS are described. CONTENTS Introduction .......................................................................................................................... 280 Silicone Rubber Polymers .................................................................................................... 280 Key Words: Polydimethyl Siloxane (PDMS) Cross-linking
    [Show full text]
  • Labeling and Synthesis of Estrogens and Their Metabolites
    Labeling and Synthesis of Estrogens and Their Metabolites Paula Kiuru University of Helsinki Faculty of Science Department of Chemistry Laboratory of Organic Chemistry P.O. Box 55, 00014 University of Helsinki, Finland ACADEMIC DISSERTATION To be presented with the permission of the Faculty of Science of the University of Helsinki, for public criticism in Auditorium A110 of the Department of Chemistry, A. I. Virtasen Aukio 1, Helsinki, on June 18th, 2005 at 12 o'clock noon Helsinki 2005 ISBN 952-91-8812-9 (paperback) ISBN 952-10-2507-7 (PDF) Helsinki 2005 Valopaino Oy. 1 ABSTRACT 3 ACKNOWLEDGMENTS 4 LIST OF ORIGINAL PUBLICATIONS 5 LIST OF ABBREVIATIONS 6 1. INTRODUCTION 7 1.1 Nomenclature of estrogens 8 1.2 Estrogen biosynthesis 10 1.3 Estrogen metabolism and cancer 10 1.3.1 Estrogen metabolism 11 1.3.2 Ratio of 2-hydroxylation and 16α-hydroxylation 12 1.3.3 4-Hydroxyestrogens and cancer 12 1.3.4 2-Methoxyestradiol 13 1.4 Structural and quantitative analysis of estrogens 13 1.4.1 Structural elucidation 13 1.4.2 Analytical techniques 15 1.4.2.1 GC/MS 16 1.4.2.2 LC/MS 17 1.4.2.3 Immunoassays 18 1.4.3 Deuterium labeled internal standards for GC/MS and LC/MS 19 1.4.4 Isotopic purity 20 1.5 Labeling of estrogens with isotopes of hydrogen 20 1.5.1 Deuterium-labeling 21 1.5.1.1 Mineral acid catalysts 21 1.5.1.2 CF3COOD as deuterating reagent 22 1.5.1.3 Base-catalyzed deuterations 24 1.5.1.4 Transition metal-catalyzed deuterations 25 1.5.1.5 Deuteration without catalyst 27 1.5.1.6 Halogen-deuterium exchange 27 1.5.1.7 Multistep labelings 28 1.5.1.8 Summary of deuterations 30 1.5.2 Enhancement of deuteration 30 1.5.2.1 Microwave irradiation 30 1.5.2.2 Ultrasound 31 1.5.3 Tritium labeling 32 1.6 Deuteration estrogen fatty acid esters 34 1.7 Synthesis of 2-methoxyestradiol 35 1.7.1 Halogenation 35 1.7.2 Nitration of estrogens 37 1.7.3 Formylation 38 1.7.4 Fries rearrangement 39 1.7.5 Other syntheses of 2-methoxyestradiol 39 1.7.6 Synthesis of 4-methoxyestrone 40 1.8 Synthesis of 2- and 4-hydroxyestrogens 41 2.
    [Show full text]
  • Estrogen Receptor Ligands for Targeting Breast Tumours: a Brief Outlook on Radioiodination Strategies
    124 Current Radiopharmaceuticals, 2012, 5, 124-141 Estrogen Receptor Ligands for Targeting Breast Tumours: A Brief Outlook on Radioiodination Strategies Maria Cristina Oliveira*,1,2, Carina Neto1,2, Lurdes Gano1,2, Fernanda Marques1,2, Isabel Santos1,2, Thies Thiemann2,3, Ana Cristina Santos2,4, Filomena Botelho2,4 and Carlos F. Oliveira2,5 1Unidade de Ciências Químicas e Radiofarmacêuticas, Instituto Tecnológico e Nuclear, Sacavém, Portugal; 2Centro de Investigação em Meio Ambiente Genética e Oncobiologia (CIMAGO); 3Faculty of Science, United Arab Emirates University, United Arab Emirates; 4Instituto de Biofísica/Biomatemática, IBILI, FMUC, Coimbra, Portugal; 5Clínica Ginecológica, FMUC, Coimbra, Portugal Abstract: The design and development of radiolabelled estradiol derivatives has been an important area of research due to their recognized value in breast cancer management. The estrogen receptor (ER) is a relevant biomarker in the diagnosis, prognosis and prediction of the therapeutic response in estrogen receptor positive breast tumours. Hence, many radioligands based on estradiol derivatives have been proposed for targeted functional ER imaging. The main focus of this review is to survey the current knowledge on estradiol-based radioiodinated receptor ligands synthesis for breast tumour functional imaging. The main preclinical and clinical achievements in the field will also be briefly presented to make the manuscript more comprehensive. Keywords: Breast cancer, estradiol, estrogen receptor, radioiodination, SPECT, tumor targeting. expressed primarily in the brain, bone and vascular 1. INTRODUCTION epithelium. Breast cancer is the most malignant type of diagnosed Given the broad clinical application in women welfare of cancer among women and still remains a major cause of ligands that modulate the ER, several classes of ER targeting death in the western world.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Directory of Suppliers
    Directory of Suppliers The directory lists the major suppliers of instruments and acces­ sories. A more complete list can be found in J. Gas Chromatog., June 1965. Suppliers are generally listed under one heading only although many of the large instrument manufacturers supply most of the listed accessories and supplies. INSTRUMENTS AMERICAN INSTRUMENT CO., INC. MICRO-TEK INSTRUMENTS, INC. 8030 Georgia Avenue P. O. Box 15409 Silver Spring, Maryland 20910 Baton Rouge. Louisiana BARBER-COLMAN COMPANY NESTER/FAUST Rockford. Illinois 2401 Ogletown Road Newark, Delaware BECKMAN INSTRUMENTS. INC. 2500 Harbor Boulevard PACKARD INSTRUMENT CO .. INC. Fullerton. California 92634 2200 Warrenville Road Downers Grove, Illinois 60515 BURRELL CORPORATION 2223 Fifth Avenue THE PERKIN-ELMER CORP. Pittsburgh 19, Pennsylvania 870 Main Avenue Norwalk, Connecticut CARY INSTRUMENTS Applied Physics Corporation 2724 South Peck Road WARNER-CHILCOTT LABORATORIES Monrovia, California Instrument Division 200 South Garrard Boulevard F & M SCIENTIFIC CORP. Richmond, California Route 41 and Starr Road Avondale, Pennsyl vania WILKENS INSTRUMENT & RESEARCH INC. 2700 Mitchell Drive, Box 313 GLOWALL CORPORATION Walnut Creek. California 2530 Wyandotte Road Willow Grove, Pennsylvania BECKER-DELFT (Julian H. Becker N.V.) JARRELL-ASH COMPANY Vulcanusweg 113, P. O. Box 219 590 Lincoln Street Delft, Holland Waltham, Massachusetts 02154 BODENSEEWERK PERKIN ELMER & CO. LOENCO, INC. GmbH 2092 North Lincoln Avenue 777 Uberlingen/Bodensee Altadena, California 91002 West Germany 267 268 Directory of Suppliers CARLO ERBA S.p.A. JOHNS-MANVILLE PRODUCTS CORP. Via Carlo Imbonati, 24 Celite Division Milano, Italy 22 East 40th Street New York, New York GAS CHROMATOGRAPHY LIMITED Boyn Valley Road, Maidenhead MAY & BAKER LIMITED Berkshire, England Dagenham Essex, England W.
    [Show full text]
  • LGC Standards Pharmacopoeial Reference Standards 2014
    LL CTS INKSP RODUTO A L P ITH W WEBSHO LGC Standards Pharmacopoeial reference standards 2014 FOR STANDARDS WITH CofA SEE OUR CATALOGUE: PHARMACEUTICAL IMPURITIES AND PRIMARY REFERENCE STANDARDS LGC Quality – ISO Guide 34 • GMP/GLP • ISO 9001 • ISO/IEC 17025 • ISO/IEC 17043 Pharmaceutical impurities Code Product CAS No. CS Price Unit Adiphenine Hydrochloride O LGC Standards N O MM1172.00 Adiphenine Hydrochloride 50-42-0 A 250mg HCl Pharmaceutical impurities and Adrenaline Tartrate OH H OH O OH primary reference standardsMM0614.00 2014 N OH Adrenaline Tartrate 51-42-3 A 500mg OH OH O OH OH H MM0614.02 L-Adrenaline 51-43-4 A 500mg OH N OH Imp. C (EP) as Hydrochloride: 1-(3,4-Di- O H OH MM0614.13 hydroxyphenyl)-2-(methylamino)ethanone 62-13-5 A 100mg N HCl Hydrochloride (Adrenalone Hydrochloride) OH (1R)-1-(3,4-Dihydroxyphenyl)-2- OH O S O MM0614.01 methylaminoethanesulphonic Acid H 78995-75-2 A 100mg OH N (Adrenaline -Sulphonate) OH Alanine NH2 MM0566.00 Alanine 56-41-7 A 500mg OH O Imp. A (Pharmeuropa): (2 S)-2-Aminobutanedioic Acid O NH 2 MM0567.00 OH (Aspartic Acid) 56-84-8 A 500mg OH O Albendazole O H MM0382.00 Albendazole N O 54965-21-8 A 500mg N H S N Imp. A (EP): 5-(Propylsulphanyl)-1H- H MM0382.01 N 80983-36-4 A 100mg NH2 benzimidazol-2-amine S N O H Imp. B (EP): Methyl [5-Propylsulphinyl)- N O MM0382.02 N 54029-12-8 A 100mg H 1H-benzimidazol-2-yl]carbamate S N O O H Imp.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317850 A1 Hewitt Et Al
    US 20080317850A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317850 A1 Hewitt et al. (43) Pub. Date: Dec. 25, 2008 (54) BUCCAL DELIVERY SYSTEM Publication Classification (51) Int. Cl. (76) Inventors: Ernest Alan Hewitt, New South A69/20 (2006.01) Wales (AU); Richard James A6II 47/34 (2006.01) Stenlake, New South Wales (AU) A 6LX 3/57 (2006.01) A6II 3/565 (2006.01) Correspondence Address: A6II 3/568 (2006.01) REED SMITH LLP A6II 3/66 (2006.01) P.O. BOX 488 (52) U.S. Cl. ......... 424/464; 424/486; 514/177: 514/182: PITTSBURGH, PA 15230-0488 (US) 514/178; 514/108 (57) ABSTRACT (21) Appl. No.: 11/910,902 A buccal delivery system capable of being blended in a nor 1-1. mal dry powder process and compressed using a standard (22) PCT Filed: Apr. 7, 2006 tabletting machine, said buccal delivery system comprising a matrix of: (a) an effective amount of one or more active (86). PCT No.: PCT/AU2OO6/OOO472 ingredients; (b) an amount of one or more polyethylene gly cols orderivatives thereofhaving a molecular weight between S371 (c)(1), 1000 to 8000 sufficient to provide the required hardness and (2), (4) Date: Feb. 5, 2008 time for dissolution of the matrix; (c) 0.05-2% by weight of the total matrix of one or more Suspending agents; (d) 0.05 (30) Foreign Application Priority Data 2% by weight of the total matrix of one or more flowing agents; and (e) 0.05-2% by weight of the total matrix of one or Apr.
    [Show full text]
  • Fundamentals of Medicinal Chemistry
    Fundamentals of Medicinal Chemistry Gareth Thomas University of Portsmouth, UK Fundamentals of Medicinal Chemistry Fundamentals of Medicinal Chemistry Gareth Thomas University of Portsmouth, UK Copyright # 2003 by John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England National 01243 779777 International (þ44) 1243 779777 e-mail (for orders and customer service enquiries): [email protected] Visit our Home Page on http://www.wiley.co.uk or http://www.wiley.com All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London, UK W1P 9 HE, without the permission in writing of the publisher. Other Wiley Editorial Offices John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158–0012, USA Wiley-VCH Verlag GmbH, Pappelallee 3, D-69469 Weinheim, Germany John Wiley & Sons (Australia) Ltd, 33 Park Road, Milton, Queensland 4064, Australia John Wiley & Sons (Asia) Pte Ltd, 2 Clementi Loop #02–01, Jin Xing Distripark, Singapore 0512 John Wiley & Sons (Canada) Ltd, 22 Worcester Road, Rexdale, Ontario M9W 1L1, Canada Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books Library of Congress Cataloging-in-Publication Data Thomas, Gareth, Dr. Fundamentals of medicinal chemistry / Gareth Thomas. p. cm.
    [Show full text]